FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2939131851> ?p ?o ?g. }

• W2939131851 endingPage "1269" @default.
• W2939131851 startingPage "1259" @default.
• W2939131851 abstract "Abstract Background The objective of this study was to characterize the clinicopathologic features of sicca syndrome associated with immune checkpoint inhibitor (ICI) therapy. Subjects, Materials, and Methods Consecutive patients with new or worsening xerostomia in the setting of ICI treatment for benign or malignant neoplastic disease were evaluated, including labial salivary gland biopsy (LSGB). Results Twenty patients (14 male; median age 57 years) had metastatic melanoma (n = 10), metastatic carcinoma (n = 6), or recurrent respiratory papillomatosis (n = 4) and were being treated with avelumab (n = 8), nivolumab (n = 5), pembrolizumab (n = 4), nivolumab/ipilimumab (n = 2), and M7824, a biologic targeting programmed cell death ligand 1 (PD-L1) and transforming growth factor ß (n = 1). Four had pre-existing autoimmune disease. Nineteen had very low whole unstimulated saliva flow; six had new dry eye symptoms. The median interval between ICI initiation and dry mouth onset was 70 days. Rheumatoid factor and anti-Sjögren's Syndrome-related Antigen A (Anti-SSA) were both positive in two subjects. LSGB showed mild-to-severe sialadenitis with diffuse lymphocytic infiltration and architectural distortion. There were lymphocytic aggregates in eight patients, composed mainly of CD3+ T cells with a slight predominance of CD4+ over CD8+ T cells. ICI targets (e.g., programmed cell death 1 and PD-L1) were variably positive. In direct response to the advent of the sicca immune-related adverse event, the ICI was held in 12 patients and corticosteroids were initiated in 10. Subjective improvement in symptoms was achieved in the majority; however, salivary secretion remained very low. Conclusion ICI therapy is associated with an autoimmune-induced sicca syndrome distinct from Sjögren's syndrome, often abrupt in onset, usually developing within the first 3 months of treatment, and associated with sialadenitis and glandular injury. Improvement can be achieved with a graded approach depending on severity, including withholding the ICI and initiating corticosteroids. However, profound salivary flow deficits may be long term. Implications for Practice Sicca syndrome has been reported as an immune-related adverse event (irAE) of immune checkpoint inhibitor therapy (ICI) for neoplastic diseases. Severe dry mouth (interfering with eating or sleeping) developed abruptly, typically within 90 days, after initiation of ICI therapy. Salivary gland biopsies demonstrated mild-to-severe sialadenitis distinct from Sjögren's syndrome, with diffuse T-cell lymphocytic infiltration and acinar injury. Recognition of the cardinal features of ICI-induced sicca will spur appropriate clinical evaluation and management, including withholding of the ICI and corticosteroid, initiation. This characterization should help oncologists, rheumatologists, and oral medicine specialists better identify patients that develop ICI-induced sicca to initiate appropriate clinical evaluation and therapy to reduce the likelihood of permanent salivary gland dysfunction." @default.
• W2939131851 created "2019-04-25" @default.
• W2939131851 creator A5003591185 @default.
• W2939131851 creator A5014494747 @default.
• W2939131851 creator A5018878859 @default.
• W2939131851 creator A5019378601 @default.
• W2939131851 creator A5036748733 @default.
• W2939131851 creator A5042747759 @default.
• W2939131851 creator A5044285326 @default.
• W2939131851 creator A5050363088 @default.
• W2939131851 creator A5055846414 @default.
• W2939131851 creator A5066468457 @default.
• W2939131851 creator A5070669850 @default.
• W2939131851 creator A5072560123 @default.
• W2939131851 creator A5075372434 @default.
• W2939131851 creator A5077113191 @default.
• W2939131851 creator A5082550776 @default.
• W2939131851 creator A5083000419 @default.
• W2939131851 creator A5083863078 @default.
• W2939131851 date "2019-04-17" @default.
• W2939131851 modified "2023-10-17" @default.
• W2939131851 title "Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy" @default.
• W2939131851 cites W1676625338 @default.
• W2939131851 cites W1977196127 @default.
• W2939131851 cites W1978468215 @default.
• W2939131851 cites W1984545852 @default.
• W2939131851 cites W1989212709 @default.
• W2939131851 cites W2005331689 @default.
• W2939131851 cites W2019607817 @default.
• W2939131851 cites W2024334721 @default.
• W2939131851 cites W2033897823 @default.
• W2939131851 cites W2057829700 @default.
• W2939131851 cites W2085894167 @default.
• W2939131851 cites W2101057221 @default.
• W2939131851 cites W2101653483 @default.
• W2939131851 cites W2105964176 @default.
• W2939131851 cites W2132409442 @default.
• W2939131851 cites W2143772132 @default.
• W2939131851 cites W2154612768 @default.
• W2939131851 cites W2277326116 @default.
• W2939131851 cites W2291096806 @default.
• W2939131851 cites W2347141054 @default.
• W2939131851 cites W2413514895 @default.
• W2939131851 cites W2441690768 @default.
• W2939131851 cites W2526221434 @default.
• W2939131851 cites W2540091234 @default.
• W2939131851 cites W2547133566 @default.
• W2939131851 cites W2560367415 @default.
• W2939131851 cites W2565782504 @default.
• W2939131851 cites W2572174216 @default.
• W2939131851 cites W2592187743 @default.
• W2939131851 cites W2600419100 @default.
• W2939131851 cites W2743670010 @default.
• W2939131851 cites W2755024608 @default.
• W2939131851 cites W2786816161 @default.
• W2939131851 cites W2789417379 @default.
• W2939131851 cites W2795507797 @default.
• W2939131851 cites W2804191059 @default.
• W2939131851 cites W2885545151 @default.
• W2939131851 doi "https://doi.org/10.1634/theoncologist.2018-0823" @default.
• W2939131851 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6738284" @default.
• W2939131851 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30996010" @default.
• W2939131851 hasPublicationYear "2019" @default.
• W2939131851 type Work @default.
• W2939131851 sameAs 2939131851 @default.
• W2939131851 citedByCount "112" @default.
• W2939131851 countsByYear W29391318512019 @default.
• W2939131851 countsByYear W29391318512020 @default.
• W2939131851 countsByYear W29391318512021 @default.
• W2939131851 countsByYear W29391318512022 @default.
• W2939131851 countsByYear W29391318512023 @default.
• W2939131851 crossrefType "journal-article" @default.
• W2939131851 hasAuthorship W2939131851A5003591185 @default.
• W2939131851 hasAuthorship W2939131851A5014494747 @default.
• W2939131851 hasAuthorship W2939131851A5018878859 @default.
• W2939131851 hasAuthorship W2939131851A5019378601 @default.
• W2939131851 hasAuthorship W2939131851A5036748733 @default.
• W2939131851 hasAuthorship W2939131851A5042747759 @default.
• W2939131851 hasAuthorship W2939131851A5044285326 @default.
• W2939131851 hasAuthorship W2939131851A5050363088 @default.
• W2939131851 hasAuthorship W2939131851A5055846414 @default.
• W2939131851 hasAuthorship W2939131851A5066468457 @default.
• W2939131851 hasAuthorship W2939131851A5070669850 @default.
• W2939131851 hasAuthorship W2939131851A5072560123 @default.
• W2939131851 hasAuthorship W2939131851A5075372434 @default.
• W2939131851 hasAuthorship W2939131851A5077113191 @default.
• W2939131851 hasAuthorship W2939131851A5082550776 @default.
• W2939131851 hasAuthorship W2939131851A5083000419 @default.
• W2939131851 hasAuthorship W2939131851A5083863078 @default.
• W2939131851 hasBestOaLocation W29391318511 @default.
• W2939131851 hasConcept C121608353 @default.
• W2939131851 hasConcept C126322002 @default.
• W2939131851 hasConcept C143998085 @default.
• W2939131851 hasConcept C159654299 @default.
• W2939131851 hasConcept C163764329 @default.
• W2939131851 hasConcept C197934379 @default.
• W2939131851 hasConcept C203014093 @default.
• W2939131851 hasConcept C2777701055 @default.

• next